ABBV today
$299.54+$4.56 (+1.55%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourBullish
1 hourAscending Triangle
15 minBullish
5 minConsolidating
Daily trend turns down below $278.01
Key levels
Support$298.74
Support$281.07
Latest news & SEC filings
AnalystBerenberg raises AbbVie target to $305 from $275
DealAbbVie Ventures joins $25 million financing round for PsiThera
ProductAllergan Aesthetics reports Phase 4 results for aesthetic treatments in GLP-1 patients
All ABBV news →About AbbVie
AbbVie discovers, makes and markets prescription drugs and medical aesthetic products. It focuses on treatments for immune system disorders, brain and nerve conditions, cancer, eye diseases, and cosmetic procedures, with medicines such as Skyrizi, Rinvoq, Humira, Botox, Vraylar, Imbruvica and Juvederm. Its goods reach buyers around the globe, including large drug distributors, hospitals, clinics, pharmacies, government health programs and physicians.
Based on the company's 10-K filed Feb 20, 2026.
NYSE · Healthcare
AbbVie Inc. (ABBV)
What Is the Price Target for ABBV?
SEPT Low Target
$247.00
SEPT Mid Target
$315.00
SEPT High Target
$346.00
Analyst Consensus
$315.00
Is ABBV a Buy or Sell Right Now?
Thesis
- •Revenue growing 8.6% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ABBV.
Start Free Trial →Is ABBV Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, Analyst Consensus
Fair Value
$296.27
31
Moat Score
NONE
6/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with ABBV?
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
BUYING
5 buys / 15 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ABBV Growth Story
Revenue YoY
8.6%
3yr Revenue CAGR
1.8%
EPS Growth YoY
-1.26%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for ABBV
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ABBV, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 13:04:24 | $294.98 | 169,502 | $$50.0M | SELL |
| 13:04:24 | $294.98 | 55,012 | $$16.2M | SELL |
| 13:04:24 | $294.98 | 8,572 | $$2.5M | SELL |
| 23:57:47 | $294.98 | 1,355 | $$400K | SELL |
| 22:25:52 | $294.98 | 68,760 | $$20.3M | SELL |
5 dark pool trades shown · $$89.4M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for AbbVie Inc. (ABBV) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ABBV — frequently asked questions
What is ABBV stock price today?
AbbVie Inc. (ABBV) is at $299.54, up 1.55% (+$4.56) at the Nov 12, 2026 close.
Why is ABBV stock moving today?
Latest ABBV news — Nov 11, 2026: Berenberg raises AbbVie target to $305 from $275 · Nov 10, 2026: AbbVie Ventures joins $25 million financing round for PsiThera
Why did ABBV stock move on Oct 30, 2026?
AbbVie reported third-quarter 2026 adjusted EPS of $3.82 and sales of $17.404 billion, both above analyst estimates of $3.75 and $17.314 billion, and raised its full-year 2026 sales guidance to $67.800 billion from $67.600 billion while lifting its FY2026 adjusted EPS outlook to $13.95-$13.99. The company also increased its dividend and raised its 2026 forecast, though its fourth-quarter adjusted EPS guidance of $3.83-$3.87 sits below analyst estimates even as the $18.400 billion sales view is above them.
What is the ABBV price target?
The average analyst price target for ABBV is $315.00, ranging from $247 to $346, based on 17 analysts. Latest: Cantor Fitzgerald maintains on Nov 2, 2026.
What do analysts rate ABBV?
Analyst ratings for ABBV: 2 Buy, 45 Hold, 0 Sell — consensus Hold.
Did ABBV beat earnings?
ABBV last reported on Oct 30, 2026: EPS $3.82 vs $3.73 expected — a beat of 2.4%.
What is ABBV's P/E ratio?
ABBV trades at a P/E of 50.6 vs a Healthcare average of 17.2.
Does ABBV pay a dividend?
Yes. ABBV's dividend yield is 2.85%.
How much debt does ABBV have?
AbbVie Inc. reported $72.2B of debt and $10.8B of cash (Sep 30, 2026).
What are ABBV support and resistance levels?
Support: $298.74, $281.07, $268.93.
What are insiders doing with ABBV?
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
What is the latest news on ABBV?
Nov 11, 2026: Berenberg raises AbbVie target to $305 from $275 · Nov 10, 2026: AbbVie Ventures joins $25 million financing round for PsiThera · Nov 9, 2026: Allergan Aesthetics reports Phase 4 results for aesthetic treatments in GLP-1 patients